Xeljanz (tofacitinib), Cosentyx (secukinumab), and Trulicity (dulaglutide), manufactured by, respectively, Pfizer (PFE), Novartis (NVS), and Eli Lilly (LLY), are among the 15 latest drugs chosen by the Centers for Medicare & Medicaid Services for Medicare Part D price negotiations.
Other drugs are AbbVie’s (ABBV) Botox (onabotulinumtoxinA), Bristol Myers Squibb’s (BMY) Orencia (abatacept), and Gilead Sciences’ (GILD) Biktarvy (bictegravir/emtricitabine/tenofovir).
CMS said that between November 2024 and October 2025, about 1.8M individuals with Part D or Medicare Part B coverage used the 15 drugs on the list accounting for $27B in prescription drug spending.
The negotiated prices will go into effect in 2028.
The complete list of the 15 drugs is available here.
